Inscobee Inc.
SEC insider (Form 3/4/5 filer). CIK 0002057997. 10% Owner at Apimeds Pharmaceuticals US, Inc. (APUS). 5 reported Form 4/5 transactions since Sep 2024; latest on May 12, 2025. Located in SEOUL, M5.
Companies Inscobee Inc. has filed insider reports for
- Apimeds Pharmaceuticals US, Inc. (APUS): 10% Owner
Inscobee Inc.
CIK: 0002057997
Transaction Breakdown
Open Market Buys (P)1 (20.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)4 (80.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
APUS
Apimeds Pharmaceuticals US, Inc.
10% Owner
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- May 12, 2025APUS
Apimeds Pharmaceuticals US, Inc.
ConversionDirect71.1K shares at avg. $2.60$185K - May 12, 2025APUS
Apimeds Pharmaceuticals US, Inc.
ConversionDirect44K shares at avg. $2.60$115K - May 12, 2025APUS
Apimeds Pharmaceuticals US, Inc.
PurchaseDirect500K shares at avg. $4.00$2.0M - May 12, 2025APUS
Apimeds Pharmaceuticals US, Inc.
ConversionIndirect182K shares at avg. $2.60$473K - May 12, 2025APUS
Apimeds Pharmaceuticals US, Inc.
ConversionIndirect71.1K shares at avg. $2.60$185K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Conversion | 71,090 | $2.60 | $184,834 | Direct |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Conversion | 44,041 | $2.60 | $114,507 | Direct |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Purchase | 500,000 | $4.00 | $2,000,000 | Direct |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Conversion | 182,002 | $2.60 | $473,205 | Indirect |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Conversion | 71,090 | $2.60 | $184,834 | Indirect |
1-5 of 5 transactions